the update which has been buried by the usual naysayers,is repeated below for everybody's benefit
we are not yet told where the money came from
this could be because of the non disclosure agreements NNLX has with its bigger partners-typically such nda's are take it or leave it and require everything to be disclosed to be approved by the bigger partner
re financials last we knew income grew over 400% year over year for nnlx- financials published on otcmarkets com would cost $4200/year for otc filing fees and reporting service,and probably another 1500 or more in accounting and legal fees for a total of ca 6k/yr times 5 years since last published financials = 30k nnlx has streamlined all costs to avoid the usual burial associated with a startup and to aviod toxic financing- they could report such on the website if allowed to do so by the various nda's they've had with bigger partners since then
when large co's file sec reports, sometimes portions of the report or the entire report is sealed,either for a stated time or a nonstated time -corporate secrecy and espionage sometimes exceeds that of goverments
dont have time for more right now-if you want everything detailed a biotech startup would be the one of the last stocks to buy into
New Update for UTI test
NanoLogix is pleased to provide this brief update on the development on the N-Assay Bacteria Diagnostic Screening/Pretest. The development work in the UK by a company with Global operations began on October 1st and is in the first of four phases that will carry through to patient studies in Houston planned for 2020. This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI (Urinary tract infections) projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
In step with the development plans, NanoLogix has requested assistance from the Youngstown State University's Career Center in locating and hiring two laboratory personnel for our Ohio Lab. These personnel will configure the N-Assay Diagnostic tests to conform with the results and efforts of the UK development company.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
we are not yet told where the money came from
this could be because of the non disclosure agreements NNLX has with its bigger partners-typically such nda's are take it or leave it and require everything to be disclosed to be approved by the bigger partner
re financials last we knew income grew over 400% year over year for nnlx- financials published on otcmarkets com would cost $4200/year for otc filing fees and reporting service,and probably another 1500 or more in accounting and legal fees for a total of ca 6k/yr times 5 years since last published financials = 30k nnlx has streamlined all costs to avoid the usual burial associated with a startup and to aviod toxic financing- they could report such on the website if allowed to do so by the various nda's they've had with bigger partners since then
when large co's file sec reports, sometimes portions of the report or the entire report is sealed,either for a stated time or a nonstated time -corporate secrecy and espionage sometimes exceeds that of goverments
dont have time for more right now-if you want everything detailed a biotech startup would be the one of the last stocks to buy into
New Update for UTI test
NanoLogix is pleased to provide this brief update on the development on the N-Assay Bacteria Diagnostic Screening/Pretest. The development work in the UK by a company with Global operations began on October 1st and is in the first of four phases that will carry through to patient studies in Houston planned for 2020. This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI (Urinary tract infections) projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
In step with the development plans, NanoLogix has requested assistance from the Youngstown State University's Career Center in locating and hiring two laboratory personnel for our Ohio Lab. These personnel will configure the N-Assay Diagnostic tests to conform with the results and efforts of the UK development company.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
A direct link to the PowerPoint is here:
http://nanologix.com/downloads/N-ASSAY-4-29-2019.pptx
It is also available on our website at: http://nanologix.com/
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
Further updates will occur as warranted.
2
1
